Teva Pharmaceutical Industries (NYSE:TEVA) Updates FY 2025 Earnings Guidance

Teva Pharmaceutical Industries (NYSE:TEVA) updated its FY 2025 earnings guidance on Monday. The company provided earnings per share guidance of 2.550-2.650 for the period, compared to the consensus earnings per share estimate of 2.590. The company issued revenue guidance of $16.8 billion-$17.0 billion, compared to the consensus revenue estimate of $16.9 billion.

Teva Pharmaceutical Industries Price Performance

NYSE:TEVA opened at $32.03 on Monday. Teva Pharmaceutical Industries has a 52 week low of $12.47 and a 52 week high of $32.91. The company has a debt-to-equity ratio of 2.31, a quick ratio of 0.82 and a current ratio of 1.11. The firm’s 50-day simple moving average is $28.04 and its 200 day simple moving average is $21.60. The firm has a market cap of $36.73 billion, a price-to-earnings ratio of 53.38, a P/E/G ratio of 1.86 and a beta of 0.66.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 8th. Piper Sandler upped their target price on Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the company an “overweight” rating in a research report on Monday, December 22nd. Barclays assumed coverage on Teva Pharmaceutical Industries in a report on Tuesday, December 9th. They set an “overweight” rating and a $35.00 target price on the stock. Bank of America boosted their price target on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Finally, The Goldman Sachs Group increased their price objective on shares of Teva Pharmaceutical Industries from $31.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, December 19th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of “Buy” and an average price target of $33.67.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 200,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $24.11, for a total value of $4,822,000.00. Following the sale, the director owned 495,000 shares in the company, valued at $11,934,450. This trade represents a 28.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, VP Richard Daniell sold 115,468 shares of the business’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $28.68, for a total transaction of $3,311,622.24. Following the sale, the vice president directly owned 48,384 shares in the company, valued at approximately $1,387,653.12. The trade was a 70.47% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 622,060 shares of company stock worth $17,076,965 in the last 90 days. 0.55% of the stock is currently owned by company insiders.

More Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Teva agreed with Royalty Pharma on up to $500 million of funding to accelerate development of its anti‑IL‑15 antibody TEV‑‘408 for vitiligo; emerging Phase 1b data reportedly support IL‑15 as a therapeutic target and Teva expects to share trial results during 2026. This is a major non‑dilutive financing and creates a clear clinical catalyst. Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
• Positive Sentiment: Truist raised its price target on TEVA to $36 from $32 and kept a Buy rating, citing continued strength in the affordable medicines theme — a supportive analyst view that can lift investor sentiment and valuation expectations. Truist Lifts PT on Teva Pharmaceutical Industries (TEVA) to $36 From $32
• Positive Sentiment: A Wall Street Zen upgrade to Strong‑Buy adds to positive analyst/quant sentiment and may attract momentum flows and new investors. Teva Pharmaceutical Industries (NYSE:TEVA) Upgraded to Strong-Buy at Wall Street Zen
• Positive Sentiment: Coverage noting high institutional ownership and recent weekly gains (stock was up about 3.4% last week) underscores demand from large holders and recent momentum that can support the share price going forward. Teva Pharmaceutical Industries Limited’s (NYSE:TEVA) high institutional ownership speaks for itself as stock continues to impress, up 3.4% over last week
• Neutral Sentiment: Teva’s CEO Richard Francis will present at the J.P. Morgan Healthcare Conference on Jan. 13 to outline the “pivot to growth” strategy — this is an opportunity for management to provide updates, but impact depends on whether new financial or clinical detail is disclosed. Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference

Institutional Trading of Teva Pharmaceutical Industries

Several hedge funds and other institutional investors have recently made changes to their positions in TEVA. CIBC Private Wealth Group LLC increased its stake in shares of Teva Pharmaceutical Industries by 15.5% in the third quarter. CIBC Private Wealth Group LLC now owns 4,020 shares of the company’s stock valued at $81,000 after buying an additional 540 shares during the period. CIBC Bancorp USA Inc. bought a new stake in Teva Pharmaceutical Industries during the 3rd quarter worth approximately $234,000. Danske Bank A S bought a new stake in Teva Pharmaceutical Industries during the 3rd quarter worth approximately $5,012,000. Advisory Services Network LLC increased its position in Teva Pharmaceutical Industries by 11.1% in the 3rd quarter. Advisory Services Network LLC now owns 53,055 shares of the company’s stock valued at $1,072,000 after acquiring an additional 5,318 shares during the period. Finally, NewEdge Advisors LLC raised its stake in shares of Teva Pharmaceutical Industries by 5.2% during the third quarter. NewEdge Advisors LLC now owns 44,150 shares of the company’s stock valued at $892,000 after acquiring an additional 2,180 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.